Venture Capital

Updated:

Glenwood Ventures

Glenwood GmbH operates as a medium-sized pharmaceutical company headquartered in Munich, Germany. The firm markets and distributes specialty pharmaceuticals...

Glenwood Ventures

Glenwood GmbH operates as a medium-sized pharmaceutical company headquartered in Munich, Germany. The firm markets and distributes specialty pharmaceuticals used to treat various diseases, with a product portfolio that includes Deflamat, Difene, Dedolor, and Catapresan. The strategy centers on international distribution of branded specialty pharmaceuticals. Glenwood maintains a globally positioned partner network that delivers products directly to pharmacies and online channels. Known brand names in the portfolio include Oramorph and Persantin. The firm operates at a single site in Munich and manages a product portfolio spanning multiple therapeutic areas. Open roles listed on its website include Manager Controlling and Senior Manager Accounting. The company's structure as a specialty pharma distributor focused on international partner networks distinguishes it from direct-to-patient pharmaceutical developers.

General information

Firm type

Venture Capital

Year founded

AUM

Undisclosed

Location

Region

Europe

Country

Germany

City

Munich

Corporate office

Munich, Germany

Sector focus

Healthcare Services

Frequently asked questions

What therapeutic areas does Glenwood Ventures cover?

The company markets and distributes specialty pharmaceuticals used to treat various diseases. Specific therapeutic indications are not detailed on its public website, but its listed brands include analgesics and cardiovascular products.

Does Glenwood develop its own drugs or operate as a distributor?

Glenwood GmbH functions primarily as a marketing and distribution company for specialty pharmaceuticals. It does not disclose in-house drug development or manufacturing operations on its website.

Which geographic markets does Glenwood serve?

The firm distributes its products internationally through a network of partners. No country-specific regulatory filings or regional revenue splits are publicly available to detail exact geographic concentrations.

What are Glenwood's most important pharmaceutical brands?

The firm's website highlights Deflamat, Difene, Dedolor, Persantin, Catapresan, and Oramorph as key products within its specialty pharma portfolio.

Who leads Glenwood Ventures?

Glenwood GmbH does not publicly name its management team or board on its website. No principal names are available from the current web presence to identify who runs the firm.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on venture capital firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Munich Venture Capital profiles